ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study To Assess The Safety And Effectiveness Of Medrol® In Acute Asthma In Indian Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00971893
Recruitment Status : Withdrawn
First Posted : September 4, 2009
Last Update Posted : October 30, 2009
Sponsor:
Information provided by:
Pfizer

Brief Summary:
The present study is designed to collect data on real world experience on use of Medrol in acute asthma in Indian patients.

Condition or disease Intervention/treatment
Asthma Drug: Oral Methylprednisolone Tablets

Detailed Description:
Sequential enrollment

Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective Study to Assess the Safety and Effectiveness of Medrol® in Acute Asthma in Indian Patients
Study Start Date : October 2009
Estimated Primary Completion Date : April 2010
Estimated Study Completion Date : April 2010


Group/Cohort Intervention/treatment
Methylprednisolone Group Drug: Oral Methylprednisolone Tablets
Oral Methylprednisolone tablets given as per locally approved prescribing information



Primary Outcome Measures :
  1. Relapse within 10 days of hospital discharge (Relapse is defined as unscheduled care at a doctor's office, a clinic, or Emergency Department (ED) for symptoms of persistent or worsening asthma after hospital discharge) [ Time Frame: 10 days after discharge ]

Secondary Outcome Measures :
  1. Relapse within 20 days of hospital discharge (Relapse is defined as above for Primary Endpoint). [ Time Frame: 20 days after discharge ]
  2. Change in PEFR (Peak Expiratory Flow Rate measured in Percentage of expected) between start of therapy and first follow up visit. [ Time Frame: 8 - 22 days after discharge ]
  3. Change in FEV1 (Forced Expiratory Volume in 1 second) between start of therapy and first follow up visit. [ Time Frame: 8 - 22 days after discharge ]
  4. Proportion of patients controlled for asthma symptoms in the last 7 days after 10 days of hospital discharge [ Time Frame: 10 days after discharge ]
  5. Proportion of patients controlled for asthma symptoms in the last 7 days after 20 days of hospital discharge [ Time Frame: 20 days after discharge ]
  6. Change in frequency in last 24 hours of inhalational Beta 2 agonist therapy between start of therapy and first follow up visit [ Time Frame: 8 - 22 days after discharge ]
  7. Physician-directed intensification of pharmacologic therapy between discharge from hospital and first follow up visit. [ Time Frame: 8 - 22 days after discharge ]
  8. Summary of adverse events in the study [ Time Frame: Baseline to 20 days after discharge ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients of Acute Asthma who have been prescribed oral Medrol tablets, will be enrolled
Criteria

Inclusion Criteria:

  • To be eligible for enrollment in this study, patients must be prescribed oral Medrol® tablets (4mg and 16 mg) for acute asthma as per the locally approved prescribing information. The prescription of Medrol® will be separated from the decision to include the patient in the study.
  • Medrol® tablets, will be prescribed to the patient by the physician according to his/her usual practice. The decision to prescribe Medrol® tablet will necessarily precede and will be independent of the decision to enroll patient into the study. Only those patients who have been prescribed Medrol® tablets will be evaluated for their potential eligibility for the study
  • Only those patients, who are ready and willing to sign an informed consent, will be included in the study
  • Subject can be contacted through telephone

Exclusion Criteria:

  • Based upon history or physical exam in the emergency department (ED) or Clinic, subjects with known or suspected cause of pulmonary symptoms other than asthma, such as COPD, CHF, pneumonia, pulmonary embolism, or angioedema
  • Any contraindication to Medrol tablet use. Contraindications of Medrol use are systemic fungal infections and known hypersensitivity to components

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00971893


Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00971893     History of Changes
Other Study ID Numbers: B0121003
First Posted: September 4, 2009    Key Record Dates
Last Update Posted: October 30, 2009
Last Verified: October 2009

Keywords provided by Pfizer:
Acute Exacerbation of Bronchial Asthma Acute Asthma

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Prednisolone acetate
Methylprednisolone acetate
Methylprednisolone
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Neuroprotective Agents
Protective Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents